{"id":"doxazosin-mesylate-extended-release","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Orthostatic hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking alpha-1 adrenergic receptors, doxazosin mesylate decreases the muscle tone in the prostate and bladder neck, allowing for improved urine flow and reduced symptoms of benign prostatic hyperplasia. This is achieved through the relaxation of smooth muscle in these areas, which in turn reduces the resistance to urine flow.","oneSentence":"Doxazosin mesylate is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:11:08.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT03339258","phase":"PHASE2","title":"A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-04-15","conditions":"Stress Disorders, Post-Traumatic","enrollment":80},{"nctId":"NCT01371851","phase":"PHASE1, PHASE2","title":"Doxazosin for Psychostimulant Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2011-06","conditions":"Methamphetamine or Cocaine Dependence","enrollment":22},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cardura XL"],"phase":"phase_2","status":"active","brandName":"Doxazosin Mesylate, Extended Release","genericName":"Doxazosin Mesylate, Extended Release","companyName":"San Francisco Veterans Affairs Medical Center","companyId":"san-francisco-veterans-affairs-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxazosin mesylate is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck, improving urine flow and reducing symptoms of benign prostatic hyperplasia. Used for Benign prostatic hyperplasia, Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}